Burgues O - Search Results

1

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies.

Vicario R, Peg V, Morancho B, Zacarias-Fluck M, Zhang J, Martínez-Barriocanal Á, Navarro Jiménez A, Aura C, Burgues O, Lluch A, Cortés J, Nuciforo P, Rubio IT, Marangoni E, Deeds J, Boehm M, Schlegel R, Tabernero J, Mosher R, Arribas J. Vicario R, et al. Among authors: burgues o. PLoS One. 2015 Jun 15;10(6):e0129876. doi: 10.1371/journal.pone.0129876. eCollection 2015. PLoS One. 2015. PMID: 26075403 Free PMC article.

2

An evaluation of the impact of technical bias on the concordance rate between primary and recurrent tumors in breast cancer.

Pérez-Fidalgo JA, Eroles P, Ferrer J, Bosch A, Burgués O, Martínez F, Bermejo B, Lluch A, González-Angulo AM. Pérez-Fidalgo JA, et al. Among authors: burgues o. Breast. 2013 Oct;22(5):974-9. doi: 10.1016/j.breast.2013.05.014. Epub 2013 Jun 25. Breast. 2013. PMID: 23809906

3

High stability of microRNAs in tissue samples of compromised quality.

Peiró-Chova L, Peña-Chilet M, López-Guerrero JA, García-Giménez JL, Alonso-Yuste E, Burgues O, Lluch A, Ferrer-Lozano J, Ribas G. Peiró-Chova L, et al. Among authors: burgues o. Virchows Arch. 2013 Dec;463(6):765-74. doi: 10.1007/s00428-013-1485-2. Epub 2013 Oct 3. Virchows Arch. 2013. PMID: 24197449

4

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial.

Alba E, Albanell J, de la Haba J, Barnadas A, Calvo L, Sánchez-Rovira P, Ramos M, Rojo F, Burgués O, Carrasco E, Caballero R, Porras I, Tibau A, Cámara MC, Lluch A. Alba E, et al. Among authors: burgues o. Br J Cancer. 2014 Mar 4;110(5):1139-47. doi: 10.1038/bjc.2013.831. Epub 2014 Jan 23. Br J Cancer. 2014. PMID: 24457911 Free PMC article. Clinical Trial.

5

Predicting response and survival in chemotherapy-treated triple-negative breast cancer.

Prat A, Lluch A, Albanell J, Barry WT, Fan C, Chacón JI, Parker JS, Calvo L, Plazaola A, Arcusa A, Seguí-Palmer MA, Burgues O, Ribelles N, Rodriguez-Lescure A, Guerrero A, Ruiz-Borrego M, Munarriz B, López JA, Adamo B, Cheang MC, Li Y, Hu Z, Gulley ML, Vidal MJ, Pitcher BN, Liu MC, Citron ML, Ellis MJ, Mardis E, Vickery T, Hudis CA, Winer EP, Carey LA, Caballero R, Carrasco E, Martín M, Perou CM, Alba E. Prat A, et al. Among authors: burgues o. Br J Cancer. 2014 Oct 14;111(8):1532-41. doi: 10.1038/bjc.2014.444. Epub 2014 Aug 7. Br J Cancer. 2014. PMID: 25101563 Free PMC article.

6

Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer.

Cejalvo JM, Pérez-Fidalgo JA, Ribas G, Burgués O, Mongort C, Alonso E, Ibarrola-Villava M, Bermejo B, Martínez MT, Cervantes A, Lluch A. Cejalvo JM, et al. Among authors: burgues o. Breast Cancer Res Treat. 2016 Nov;160(1):69-77. doi: 10.1007/s10549-016-3980-z. Epub 2016 Sep 14. Breast Cancer Res Treat. 2016. PMID: 27628192

7

The ever-evolving role of pathologists in the management of breast cancer with neoadjuvant treatment: recommendations based on the Spanish clinical experience.

Burgués O, López-García MÁ, Pérez-Míes B, Santiago P, Vieites B, García JF, Peg V. Burgués O, et al. Clin Transl Oncol. 2018 Mar;20(3):382-391. doi: 10.1007/s12094-017-1725-z. Epub 2017 Aug 9. Clin Transl Oncol. 2018. PMID: 28795336 Free article.

8

Methylation deregulation of miRNA promoters identifies miR124-2 as a survival biomarker in Breast Cancer in very young women.

Oltra SS, Peña-Chilet M, Vidal-Tomas V, Flower K, Martinez MT, Alonso E, Burgues O, Lluch A, Flanagan JM, Ribas G. Oltra SS, et al. Among authors: burgues o. Sci Rep. 2018 Sep 26;8(1):14373. doi: 10.1038/s41598-018-32393-3. Sci Rep. 2018. PMID: 30258192 Free PMC article.

9

Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement.

Colomer R, Saura C, Sánchez-Rovira P, Pascual T, Rubio IT, Burgués O, Marcos L, Rodríguez CA, Martín M, Lluch A. Colomer R, et al. Among authors: burgues o. Oncologist. 2019 May;24(5):603-611. doi: 10.1634/theoncologist.2018-0228. Epub 2019 Feb 1. Oncologist. 2019. PMID: 30710068 Free PMC article.

10

A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients.

Pineda B, Diaz-Lagares A, Pérez-Fidalgo JA, Burgués O, González-Barrallo I, Crujeiras AB, Sandoval J, Esteller M, Lluch A, Eroles P. Pineda B, et al. Among authors: burgues o. Clin Epigenetics. 2019 Feb 20;11(1):33. doi: 10.1186/s13148-019-0626-0. Clin Epigenetics. 2019. PMID: 30786922 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

57 results

Search Page

Filters